Clinical Trials Insight: 700020345
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2009
At a glance
- Drugs AEZS 112 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors AEterna Zentaris Inc
- 21 Sep 2009 Results have been reported by Aterna Zentaris in a media release.
- 21 Sep 2009 Status changed from active, no longer recruiting to completed, according to an Aterna media release.
- 22 Apr 2009 Interim results presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009).